Igor Dumbadze

705 total citations
8 papers, 238 citations indexed

About

Igor Dumbadze is a scholar working on Surgery, Urology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Igor Dumbadze has authored 8 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 3 papers in Urology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Igor Dumbadze's work include Urinary and Genital Oncology Studies (3 papers), Cancer Genomics and Diagnostics (2 papers) and PARP inhibition in cancer therapy (2 papers). Igor Dumbadze is often cited by papers focused on Urinary and Genital Oncology Studies (3 papers), Cancer Genomics and Diagnostics (2 papers) and PARP inhibition in cancer therapy (2 papers). Igor Dumbadze collaborates with scholars based in United States, United Kingdom and Spain. Igor Dumbadze's co-authors include William R. Clark, Gary D. Steinberg, Daniel A. Barocas, Vignesh T. Packiam, Dominic Curran, Alex Yeung, Ronald L. Davis, John Gutheil, Donald L. Lamm and Andrew Trainer and has published in prestigious journals such as Journal of Clinical Oncology, The American Journal of Medicine and The Journal of Urology.

In The Last Decade

Igor Dumbadze

7 papers receiving 232 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Igor Dumbadze United States	5	128	102	74	73	40	8	238
Dominic Curran United States	6	167 1.3×	128 1.3×	73 1.0×	73 1.0×	35 0.9×	8	286
Nagarajan Ramesh United States	7	89 0.7×	148 1.5×	186 2.5×	236 3.2×	23 0.6×	9	355
Kevin McGeagh United States	8	43 0.3×	91 0.9×	114 1.5×	185 2.5×	16 0.4×	11	297
Claire Biot France	6	262 2.0×	105 1.0×	99 1.3×	12 0.2×	31 0.8×	8	364
H. Van der Poel Netherlands	4	41 0.3×	165 1.6×	215 2.9×	277 3.8×	6 0.1×	10	350
Aya Maekawa Japan	10	36 0.3×	80 0.8×	60 0.8×	44 0.6×	2 0.1×	43	175
Howard Bargman Canada	10	31 0.2×	39 0.4×	27 0.4×	32 0.4×	26 0.7×	20	241
Bérengère Salomé Switzerland	8	189 1.5×	81 0.8×	47 0.6×	8 0.1×	7 0.2×	10	380
Luigia Panariello Italy	7	25 0.2×	104 1.0×	30 0.4×	13 0.2×	46 1.1×	15	203
Marcel Silva Luz Brazil	7	48 0.4×	83 0.8×	50 0.7×	63 0.9×		19	225

Countries citing papers authored by Igor Dumbadze

Since Specialization

Citations

This map shows the geographic impact of Igor Dumbadze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Dumbadze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Dumbadze more than expected).

Fields of papers citing papers by Igor Dumbadze

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor Dumbadze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Dumbadze. The network helps show where Igor Dumbadze may publish in the future.

Co-authorship network of co-authors of Igor Dumbadze

This figure shows the co-authorship network connecting the top 25 collaborators of Igor Dumbadze. A scholar is included among the top collaborators of Igor Dumbadze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Dumbadze. Igor Dumbadze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Ryan, Charles J., Wassim Abida, Alan H. Bryce, et al.. (2018). TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).. Journal of Clinical Oncology. 36(6_suppl). TPS389–TPS389. 22 indexed citations

Chowdhury, S., Ray McDermott, Josep M. Piulats, et al.. (2018). Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 29. viii273–viii273. 3 indexed citations

Packiam, Vignesh T., Donald L. Lamm, Daniel A. Barocas, et al.. (2017). An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results. Urologic Oncology Seminars and Original Investigations. 36(10). 440–447. 190 indexed citations

Lin, Daniel W., Shawn M. McGee, Kimberly Rieger‐Christ, et al.. (2014). PI-06 LATE-BREAKING ABSTRACT: THE 4KSCORE ^TM TEST AS A PREDICTOR OF HIGH-GRADE PROSTATE CANCER ON BIOPSY. The Journal of Urology. 191(4S).

Dumbadze, Igor, E. David Crawford, & William P. Mulvaney. (1979). Lymphomatoid Tumor Infiltration of Renal Veins. The Journal of Urology. 121(1). 88–89. 7 indexed citations

Dumbadze, Igor, E. David Crawford, & William P. Mulvaney. (1979). Giant Dendritic Struvite Calculus Associated with Transitional Cell Carcinoma of the Ipsilateral Renal Pelvis and Bladder: A Case Report and Review of the Literature. The Journal of Urology. 122(5). 692–693. 3 indexed citations

Crawford, E. David, et al.. (1978). Deep Venous Thrombosis Following Transurethral Resection of The Prostate: Diagnosis by Phleborheography. The Journal of Urology. 120(4). 438–441. 4 indexed citations

Dumbadze, Igor, et al.. (1978). Pelvic lipomatosis. The American Journal of Medicine. 65(6). 1021–1026. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact